Medical Use
Strensiq is a tissue non-specific alkaline phosphatase and the sole prescription medication for treating patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).
Recommended Dosage:
-For Perinatal/Infantile-Onset HPP : The advised dosage of Strensiq injection is 6 mg/kg per week, administered subcutaneously. This can be given as either 2 mg/kg three times a week or 1 mg/kg six times a week. Note that injection site reactions might limit the tolerability of the six-times-per-week regimen.
If the initial dosage is ineffective, it can be increased to 9 mg/kg per week, administered as 3 mg/kg three times a week.
-For Juvenile-Onset HPP : The recommended dosage is 6 mg/kg per week, administered subcutaneously. This can be given as either 2 mg/kg three times a week or 1 mg/kg six times a week. Similar to the perinatal/infantile-onset dosage, injection site reactions may limit the tolerability of the six-times-per-week regimen.
Caution :
Avoid using the Strensiq 80 mg/0.8 mL vial in pediatric patients weighing less than 40 kg. The systemic exposure of asfotase alfa with this higher concentration vial is lower than that achieved with other available strengths of Strensiq injection. This reduced exposure may not be suitable for this subgroup of patients.
Warning & Precautions
Hypersensitivity reactions can occur in patients receiving Strensiq vials. If a severe hypersensitivity reaction happens, discontinue the treatment immediately and start appropriate medical intervention. Patients should be closely monitored for any recurrence of severe hypersensitivity symptoms.
Localized lipodystrophy, including both lipohypertrophy and lipoatrophy, may develop at injection sites after several months of treatment with Asfotase alfa 18 mg/0.45 mL injection. Patients should use proper injection techniques and rotate injection sites to minimize this risk.
Patients undergoing therapy for HPP are at an increased risk of ectopic calcifications. Regular ophthalmology evaluations and renal ultrasounds are necessary during Strensiq treatment to monitor for signs of ophthalmic and renal ectopic calcifications, as well as any changes in vision or renal function.
Strensiq injection is not recommended during pregnancy or for women of childbearing potential who are not using effective contraception. Breastfeeding should be discontinued during treatment with Strensiq 18 mg/0.45 mL.
Documentation Availability
Documents required to import STRENSIQ to India?
STRENSIQ (asfotase alfa) injections can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing STRENSIQ (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the Generic Name for the trade name drug Strensiq®?
Asfotase alfa is a Generic Name for the trade name drug Strensiq®.
What is the Manufacturer’s Name of Strensiq®?
Strensiq® is manufactured by Alexion Pharmaceuticals, Inc.
Is Strensiq® approved by the FDA?
Yes, Strensiq® is approved by the FDA. Date of first/initial approval: October 23, 2015.
Where can I get Strensiq® at the best price in India?
To get the best Strensiq price in India, kindly get in touch with Rx4u team.
What is the dosage and form of Strensiq® supplied?
Strensiq® is supplied as an Injection: 80 mg/0.8 mL, 40 mg/mL, 28 mg/0.7 mL, or 18 mg/0.45 mL solution in single-use vials for subcutaneous administration.
What are the most common side effects of Strensiq®?
The most common side effects of Strensiq are ectopic calcifications, lipodystrophy, hypersensitivity reactions, and injection site reactions.
How much does Strensiq cost in India?
The Strensiq cost in India can vary. In order to procure Strensiq legally, you can order from www.rx4u.in.
What are the storage conditions of Strensiq®?
Vials of Strensiq must be stored under refrigerated conditions at 2°C to 8°C (36°F to 46°F) in the original carton and protected from light. After removing from refrigeration, it should be administered within 60 minutes. Avoid freezing and shaking the vials.
Is it safe to buy Strensiq® online in India?
Yes, one can buy Strensiq in India at the best price from https://rx4u.in/
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
